Introduction
- Although migraine market revenues have demonstrated almost 12% growth over
the last four years across the seven major pharmaceutical markets reaching
approximately $2.4 billion in 2003, as the market becomes increasingly
crowded, growth is predicted to slow.
Scope of this report
- Overview of current market including profiles of key brands and key events
impacting each brand during 2003-2004
- Assessment of current and future opportunities and threats in the migraine
market across the seven major pharmaceutical markets
- Global sales for leading migraine products are presented, with projections
for future performance up to 2014
- In-depth discussion of assumptions and events used in forecast analysis
Research and analysis highlights
- First-line therapy predominantly utilizes simple analgesics and NSAIDs,
despite the lack of sustained anti-migraine effect seen with these products
and the risk of rebound headaches. Commercial growth of the triptan class
has the potential to be accelerated by encouraging wider and earlier use
through patient and PCP education.
- Preventative treatment will provide further market expansion, however, the
current drugs that are likely to maximize this opportunity are the
anticonvulsants, whereas the prophylaxis market for triptans is likely to be
limited to MAM for the forecast period.
- As patent expiries take effect on the market, it is likely that the focus
on the cost of therapies will increase. Consistent physician valued
differentiation between the oral triptans is currently poor, which, if left
unchecked, will lead to significant cross-brand erosion following the launch
of generic sumatriptan.
Key reasons to read this report
- Quantify future size and scope of the migraine market and potential for
new products
- Understand key drivers to this market and predict future performance of
these compounds
- Identify hot areas of the market not targeted by competitors
ABOUT DATAMONITOR HEALTHCARE
- About the CNS pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the migraine market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Disease overview
- Etiology
- Epidemiology
- Segmentation of migraine
- Current market situation
- Strategic scoping and focus
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the migraine market
- Global opportunities and threats
- US: opportunities and threats
- Market overview
- Opportunities
- Threats
- Japan: opportunities and threats
- Market overview
- Opportunities
- Threats
- France: opportunities and threats
- Market overview
- Opportunities
- Threats
- Germany: opportunities and threats
- Market overview
- Opportunities
- Threats
- Italy: opportunities and threats
- Market overview
- Opportunities
- Threats
- Spain: opportunities and threats
- Market overview
- Opportunities
- Threats
- UK: opportunities and threats
- Market overview
- Opportunities
- Threats
CHAPTER 4 FORECAST ANALYSIS
- Factors affecting the market
- Topamax approved for migraine prophylaxis in the US
- Generic Topamax enters US market
- Forecasting assumptions and events
- 2004
- Frovatriptan launched in Italy
- 2005
- Zolmitriptan nasal spray launch in Japan
- 2006
- Frovatriptan gains approval for MAM
- MT-400 (Trexima) launched
- 2007
- Launch of donitriptan
- GSK/Aradigms needleless formulation of sumatriptan launched
- 2008
- Naratriptan launched in Japan
- Nimodipine launched
- Olcegepant launched in first market
- 2009
- Launch of almotriptan in Japan
- Generic sumatriptan enters US market
- Arius/Atrixs transmucosal formulation of sumatriptan launched
- 2010
- Naratriptan US patent expiry
- NovaDels sublingual sumatriptan formulation launched
- 2012
- Rizatriptan and frovatriptan US patent expiries
- 2013
- Zolmitriptan and eletriptan US patent expiries
- Limitations of data
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Case study: Sumatriptan patent expiry-GSKs strategic options
- Introduction
- GSKs current position in the migraine market
- The strategic challenge-facing the threat of patent expiry
- Patent expiry is not a new challenge for GSK
- Augmentin
- Wellbutrin
- Paxil
- Summary of GSKs previous patent expiry management strategies
- GSKs current and future activities to manage the threat of
sumatriptan generic erosion
- Imitrex reformulation
- Novel indication for Imitrex
- Launching a replacement drug
- Refocus on alternative oral triptan for migraine
- Inhalation delivery-a potential additional opportunity for GSK?
- Summary
- Case study: Promoting migraine prophylaxis
- Current treatments
- Anticonvulsants
- Antidepressants
- Beta-blockers
- Serotonergic agents
- Others
- Unmet needs
- Greater efficacy
- Fewer side effects
- Migraine-specific drug
- Use of triptans for prophylaxis
- Datamonitor recommendations
APPENDIX A-MARKET DATA AND MAJOR BRAND KEY FACTS
- Global migraine market data
- Triptans market data
APPENDIX B
- Contributing experts
- Bibliography
- Epidemiology
- Clinical trial data
- Websites
- Report methodology
- Standard units
- Japanese market data
- Regional launch dates for new products
- Additional information
- About Datamonitor
- About Datamonitor Healthcare
- About the CNS analysis team
- Key therapy team members
- Lynda Lynch, Director CNS
- David Abramson, Therapeutic Lead Consultant
- Disclaimer
- List of Tables
- Table 1: Prevalence of migraine in the seven major markets
- Table 2: Key triptan brands
- Table 3: Other acute migraine drugs
- Table 4: Key brands in migraine prophylaxis
- Table 5: The US migraine market sales and share
- Table 6: The Japanese migraine market sales and share
- Table 7: The French migraine market sales and share
- Table 8: The German migraine market sales and share
- Table 9: The Italian migraine market sales and shares
- Table 10: The Spanish migraine market sales and share
- Table 11: The UK migraine market sales and share
- Table 12: Comparative action across triptan brands
- Table 13: Historical sales of the leading migraine drugs ($m),
2000-03*
- Table 14: Sumatriptan: key facts
- Table 15: Naratriptan: key facts
- Table 16: Zolmitriptan: key facts
- Table 17: Rizatriptan: key facts
- Table 18: Almotriptan: key facts
- Table 19: Eletriptan: key facts
- Table 20: Frovatriptan: key facts
- List of Figures
- Figure 1: Summary of global opportunities for the migraine market and
examples of influencing strengths/weaknesses
- Figure 2: Summary of global threats for the migraine market and
examples of influencing strengths/weaknesses
- Figure 3: Summary of opportunities in the US migraine market and
examples of influencing strengths/weaknesses
- Figure 4: Summary of threats in the US migraine market and examples of
influencing strengths/weaknesses
- Figure 5: Summary of opportunities in the Japanese migraine market and
examples of influencing strengths/weaknesses
- Figure 6: Summary of threats in the Japanese migraine market and
examples of influencing strengths/weaknesses
- Figure 7: Summary of opportunities in the French migraine market and
examples of influencing strengths/weaknesses
- Figure 8: Summary of threats in the French migraine market and
examples of influencing strengths/weaknesses
- Figure 9: Summary of opportunities in the German migraine market and
examples of influencing strengths/weaknesses
- Figure 10: Summary of threats in the German migraine market and
examples of influencing strengths/weaknesses
- Figure 11: Summary of opportunities in the Italian migraine market and
examples of influencing strengths/weaknesses
- Figure 12: Summary of threats in the Italian migraine market and
examples of influencing strengths/weaknesses
- Figure 13: Summary of opportunities in the Spanish migraine market and
examples of influencing strengths/weaknesses
- Figure 14: Summary of threats in the Spanish migraine market and
examples of influencing strengths/weaknesses
- Figure 15: Summary of opportunities in the UK migraine market and
examples of influencing strengths/weaknesses
- Figure 16: Summary of threats in the UK migraine market and examples
of influencing strengths/weaknesses
医薬品
その他のカテゴリ
FAQ